| Excluded Study | Reason for Exclusion |
|---|---|
| Abe, T., Nakashima, H., Nakamura, M., Tanaka, M. Metachronous Pancreatic Ductal Adenocarcinoma (PDAC) After Resection of Branch Duct Intraductal Papillary Mucinous Neoplasms 3-Month Interval of Surveillance CT/MR Still Insufficient for Early Detection. Pancreas, 1340, 2014 | Case report on 1 patient |
| Banfi, G., Bravi, S., Ardemagni, A., Zerbi, A. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. International Journal of Biological Markers, 77-81, 1996 | Outcomes relevant to specificity and selectivity of the diagnostic test only |
| Banfi, G., Zerbi, A., Pastori, S., Parolini, D., Di Carlo, V., Bonini, P. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clinical Chemistry, 420-3, 1993 | Outcomes relevant to specificity and selectivity of the diagnostic test only |
| Barbu, S., Hutanu, I., Andren-Sandberg, A., Soroceanu, R. P., Timofte, D. Monitoring of Recurrence in Patients Radically Operated for Pancreatic Cancer. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi, 401-9, 2015. | Not a study, a clinical review |
| Beretta, E., Malesci, A., Zerbi, A., Mariani, A., Carlucci, M., Bonato, C., Ferrari, A. M., Di Carlo, V. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 2428-31, 1987. | Outcomes reporting correlation between Ca 19-9 and survival |
| Castellanos, J. A., Merchant, N. B. Intensity of follow-up after pancreatic cancer resection. Annals of Surgical Oncology 747-51, 2014 | Practice Guidelines |
| Channappa, C., Intenzo, C. M., Pappas, A., Mitchell, E. P., Carr, B., Kim, S. M., Littman, S. The use of FDG-PET CT imaging in follow up of pancreatic cancer. Clinical Nuclear Medicine, 1194, 2012 | No outcomes of interest |
| Del Chiaro, M., Segersvard, R., Nilsson, L., Blomberg, J., Rangelova, E., Ansorge, C., Pozzi-Mucelli, R., Kartalis, N., Lohr, M., Arnelo, U., Verbeke, C. Follow-up strategy for IPMN of the pancreas is safe. Pancreas, 1353, 2014 | Population = Non surgical IPMN |
| Del Chiaro, M., Segersvard, R., Nilsson, L., Blomberg, J., Rangelova, E., Ansorge, C., Pozzi-Mucelli, R., Kartalis, N., Lohr, M., Verbeke, C. The safety of follow-up for IPMN of the pancreas: A single institution experience. United European Gastroenterology Journal, A90-91, 2014 | Population = Non surgical IPMN |
| Deobald, R. G., Cheng, E. S., Ko, Y. J., Wright, F. C., Karanicolas, P. J. A qualitative study of patient and clinician attitudes regarding surveillance after a resection of pancreatic and peri-ampullary cancer. HBP, 409-15, 2015 | Qualitative study with no intervention |
| Franke, C., Klapdor, R., Meyerhoff, K., Schauman, M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer research, 2437-42, 1999 | Population = non-resected and resected, not analysed separately |
| Gigoni, R., Salemi, S., Boraschi, P., Donati, F., Perrone, V. G., Del Chiaro, M., Boggi, U., Bartolozzi, C., Falaschi, F. Pancreatic intraductal papillary mucinous neoplasms of the branch ducts: Usefullness of MR imaging and MR cholangiopancreatography in the follow-up. Pancreatology, 389, 2010 | Population = non-resected and resected, not analysed separately |
| Jung, W., Jang, J. Y., Kang, M. J., Chang, Y. R., Shin, Y. C., Chang, J., Kim, S. W. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients. HPB, 57-64, 2016 | Outcomes relevant to specificity and selectivity of the diagnostic test only |
| Klapdor, R., Bahlo, M. CA 19-9 AND CEA AS SEROLOGICAL TUMOR MARKERS (TM) FOR THE DIAGNOSIS AND FOLLOW-UP OF EXOCRINE PANCREATIC CANCER (PAPA). Anticancer research, 6830-6831, 2014 | Not a study, a clinical review |
| Klapdor, R., Lehmann, U., Bahlo, M., Schmiegel, W., Guthoff, A., Schreiber, H. W., Greten, H. CA 19-9 AND CEA IN THE FOLLOW-UP OF EXOCRINE PANCREATIC-CANCER DISEASE. Gastroenterology, 1137-1137, 1984 | Population = non-resected and resected, not analysed separately |
| Metz, J. M., Vachani, C., Hampshire, M. K., Hill-Kayser, C. E. Patient-reported outcomes after treatment for cancers of the pancreas and biliary tract. Journal of Clinical Oncology. Conference 2015. | No outcomes of interest, validation of a tool to get information on underrepresented survivorship in PC |
| Micke, O., Bruns, F., Schafer, U., Kurowski, R., Horst, E., Willich, N. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer research, 835-40, 2003 | Population = Not resected |
| Nagakawa, T., Ohta, T., Kayahara, M., Mori, K., Ueda, S., Kobayashi, K., Ueno, K., Konichi, I., Miyazaki, I. Clinicopathological evaluation of long-term survivors treated for cancer of the head of pancreas. Hepato-gastroenterology, 1865-9, 1998 | No outcomes of interest, study of predictor factors for long term survival in PC |
| Nallamothu, G., Cox, K., Heilbrun, M., Sharma, A., Adler, D. Follow-up CT scans have limited value in patients with pancreatic cancer. American Journal of Gastroenterology, S67, 2013 | Population = newly diagnosed PC not resected |
| Narasimhaiah, R., James, E., Siegmueller, C., Spalding, D., Patel, P. Pre-operative C-reactive protein (CRP) as a prognostic indicator of one year mortality following curative pancreatectomy. Intensive Care Medicine, S275, 2009 | Single post-operative CRP values (ICU inpatient) vs mortality outcomes in PC |
| Nordby, T., Hugenschmidt, H., Fagerland, M. W., Ikdahl, T., Buanes, T., Labori, K. J. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. European Journal of Surgical Oncology, 559-66, 2013 | Follow-up of records of asymptomatic vs symptomatic patients and relationship with disease progression |
| O’Reilly, E. M., Lowery, M. A. Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer Journal, 609-13, 2012 | Practice guidelines |
| Pedrazzoli, S., Sperti, C., Pasquali, C., Bissoli, S., Fiore, V., Scelzi, E., Mion, M. 18-FDG PET is very useful in the follow-up after resection of pancreatic and periampullary carcinomas. Gastroenterology, A814-815 | No specific follow-up, one off imaging 21 months (range 12-84 months) |
| Seufferlein, T., Bachet, J. B., Van Cutsem, E., Rougier, P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Journal of the European Society for Medical Oncology / ESMO, vii33-40, 2012 | Practice guidelines |
| Suzuki, S., Hatori, T., Kimijima, A., Oshima, N., Furukawa, T., Kuboki, Y., Shimizu, K., Shiratori, K., Yamamoto, M. The long-term survivors after curative resection for the pancreatic cancer should be paid attention to the remnant pancreatic cancer. Pancreatology, e77-78, 2013 | Retrospective clinical course follow-up with no intervention |
| Tai, Y. S., Chia, C. L. K., Shelat, V. G., Woon, W. W. L., Low, J. K. Incidental raised ca 19.9: Is long term follow-up beneficial? HPB, e460, 2016 | Population = undiagnosed PC in primary care |
| Tjaden, C., Michalski, C. W., Strobel, O., Giese, N., Hennche, A. K., Buchler, M. W., Hackert, T. Clinical Impact of Structured Follow-up after Pancreatic Surgery. Pancreas, 895-899, 2016 | No outcomes of interest |
| Tzeng, C. W., Abbott, D. E., Cantor, S. B., Fleming, J. B., Lee, J. E., Pisters, P. W., Varadhachary, G. R., Abbruzzese, J. L., Wolff, R. A., Ahmad, S. A., Katz, M. H. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Annals of Surgical Oncology, 2197-203, 2013 | Cost-effectiveness analysis |
| Visser, B. C., Ma, Y., Zak, Y., Poultsides, G. A., Norton, J. A., Rhoads, K. F. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB, 539-47, 2012 | Assessing guideline compliance in PC |
| Weden, S., Klemp, M., Gladhaug, I. P., Moller, M., Eriksen, J. A., Gaudernack, G., Buanes, T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. International Journal of Cancer, 1120-8, 2011 | 10-year follow-up of K-ras vaccination post phase I/II trial. Unlicensed in U.K. |
| Yamamoto, T., Kinoshita, H., Sakamoto, Y., Okada, K., Inoguchi, K., Yao, S., Kaihara, S., Hosotani, R., Yagi, S. Long-term survival after resection of pancreatic cancer: Significance of early detection and histologically curative resection. HBP, 71, 2014 | No intervention, study of predictor factors for long term survival in PC |
From: Appendix G, Excluded studies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.